Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Rock Solid, ValiRx, InternetQ, Quindell

Mon, 02nd Apr 2012 13:36

Rock Solid Images, an oil equipment, services and distribution firm, has received an offer from Thalassa Holdings to acquire up to 25.89 per cent of the company for 0.48p per share in cash. Rock Solid is concerned that Thalassa has provided no evidence that they will bring any "added economic or industrial assistance to the business in the next phase of the company's development". With regards to their own shareholdings, the directors do no propose to take up the offer. ValiRx, an AIM-quoted life science company, has conditionally raised £0.9m (before fees and expenses) following a placing of 200m new ordinary shares at a price of 0.45p per share. The proceeds will be used to further along a number of drug trials and expand its intellectual property portfolio and value. Six of the directors purchased a total of more than 10m of the shares. Mobile marketing and digital entertainment services firm InternetQ posted a rise in revenue from €37.3m to €50.1m after a rise in the number of users. Adjusted profit before tax leapt 42.2% from €2.3m to €3.3m, leading to earnings per share of €0.12. Cash and cash equivalents on December 31st was €10.6m, including restricted cash of €0.9m. "Mobile device connections have reached around 5.2bn at the end of 2011. Based on an analysis presented by Google this translates to some 3.7bn unique users. There are just 1.2 bn PCs in use worldwide," the firm said. Quindell Portfolio, a brand extension company, has acquired a further 47.7% of Ai Claims Solutions, an outsourcer for the management of motor claims. The move takes its stake to around 77.6%. The transaction cost the firm 3.1m pounds. As a result, Quindell has made an obligatory mandatory cash offer to acquire the entire issued share capital of Ai Claims not already owned by the Quindell Group. NR
More News
10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

Read more
14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

Read more
6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Raises GBP200,000 To Progress Product Development

Read more
16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

Read more
28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

Read more
28 Nov 2019 15:57

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

Read more
14 Oct 2019 13:44

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

Read more
26 Sep 2019 11:43

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

Read more
24 Sep 2019 12:40

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Read more
10 Sep 2019 13:45

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

Read more
1 Aug 2019 12:01

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

Read more
23 Jul 2019 16:25

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

Read more
26 Jun 2019 14:30

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

Read more
26 Jun 2019 10:53

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.